Drug Price Trends for NDC 00054-0742

Average Pharmacy Cost for 00054-0742

Drug Name	NDC	Price/Unit ($)	Unit	Date
ALBUTEROL HFA 90 MCG INHALER	00054-0742-87	2.24431	GM	2025-03-19
ALBUTEROL HFA 90 MCG INHALER	00054-0742-87	2.30126	GM	2025-02-19
ALBUTEROL HFA 90 MCG INHALER	00054-0742-87	2.22350	GM	2025-01-22
ALBUTEROL HFA 90 MCG INHALER	00054-0742-87	2.36448	GM	2024-12-18

Best Wholesale Price for NDC 00054-0742

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for Albuterol Sulfate Inhalers (NDC: 0054-0742)

Market Overview of Inhalable Drugs

The global inhalable drug market, which includes albuterol sulfate inhalers, has been experiencing steady growth driven by the increasing prevalence of pulmonary disorders such as asthma and Chronic Obstructive Pulmonary Disease (COPD). As of 2023, the global inhalable drug market was valued at US$ 33.61 billion and is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.82% through 2024 to 2030, reaching nearly US$ 49.95 billion[4].

Specific Market for Albuterol Sulfate Inhalers

Albuterol sulfate, a common bronchodilator, is widely used in the treatment of asthma and COPD. Here are some key points regarding its market:

Usage and Demand

• Albuterol sulfate inhalers are among the most frequently prescribed inhalers for respiratory conditions. The demand for these inhalers is consistent due to the chronic nature of the conditions they treat[4].

Geographical Market

• North America, followed by Europe, dominates the market for inhalable medications, including albuterol sulfate inhalers. This dominance is attributed to extensive awareness campaigns, advanced healthcare infrastructure, and higher disposable incomes[4].

Price Dynamics

• Historically, the cost of inhalers, including albuterol sulfate, has been a significant concern for patients. However, recent initiatives by major pharmaceutical companies are aimed at reducing the financial burden. For instance, companies like Boehringer Ingelheim, AstraZeneca, and GSK have introduced voluntary price caps of $35 per month for eligible patients, which includes some of their inhaler products[2].

Price Projections and Voluntary Price Caps

Current Pricing

• The pricing of albuterol sulfate inhalers can vary based on the manufacturer, insurance coverage, and location. However, with the introduction of voluntary price caps by major pharmaceutical companies, the out-of-pocket costs for patients are expected to decrease significantly.

Voluntary Price Caps

• As of June 1, 2024, Boehringer Ingelheim and AstraZeneca have implemented a $35 per month price cap for their respective inhaler products. GSK will follow suit by January 1, 2025. This move is expected to reduce the financial burden on patients, particularly those who are uninsured or underinsured[2].

Regulatory and Market Trends

Regulatory Environment

• The regulatory landscape is evolving to support innovation in the biopharma and biotech industries. This includes more efficient clinical trial designs and a focus on patient-centered care, which could influence the development and pricing of inhalable medications[3].

Technological Advancements

• Advances in technology, such as improved inhalation devices and new formulations, are expected to drive the market forward. These innovations could lead to more effective treatments and potentially impact pricing as competition increases[4].

Growth Projections

Market Growth

• The global inhalable drug market, including albuterol sulfate inhalers, is projected to grow at a CAGR of 5.82% from 2024 to 2030. This growth is driven by increasing awareness, improved healthcare infrastructure, and rising disposable incomes, particularly in the Asia Pacific region[4].

Regional Growth

• The Asia Pacific market is expected to grow at the fastest rate due to factors such as improved healthcare infrastructure, increased patient awareness, and higher disposable incomes[4].

Key Takeaways

• The market for albuterol sulfate inhalers is part of a larger and growing global inhalable drug market.
• Voluntary price caps introduced by major pharmaceutical companies are expected to reduce the financial burden on patients.
• Technological advancements and evolving regulatory frameworks will continue to shape the market.
• The Asia Pacific region is expected to be a key driver of growth in the coming years.

FAQs

1. What is the current market size of the global inhalable drug market?

   • The global inhalable drug market was valued at US$ 33.61 billion in 2023[4].

2. What is the expected growth rate of the global inhalable drug market?

   • The market is expected to grow at a CAGR of 5.82% from 2024 to 2030[4].

3. Which region dominates the market for inhalable medications?

   • North America currently dominates the market, followed by Europe[4].

4. What are the recent price cap initiatives for inhalers?

   • Major pharmaceutical companies like Boehringer Ingelheim, AstraZeneca, and GSK have introduced voluntary price caps of $35 per month for eligible patients[2].

5. How will technological advancements impact the market?

   • Technological advancements are expected to drive the market forward by introducing more effective treatments and improving inhalation devices, which could impact pricing and competition[4].

Sources

1. EPA - Market Characterization of the U.S. Metered Dose Inhaler Industry[1]
2. Allergy & Asthma Network - Drug Companies Step Forward with Voluntary Price Caps on Inhalers[2]
3. TFS CRO - 5 Predictions for the Biopharma and Biotech Industries in 2025[3]
4. Maximize Market Research - Inhalable Drug Market - Global Industry Analysis and Forecast[4]